Genenta Science S.p.A (GNTA) Share-based Compensation (2020 - 2025)
Genenta Science S.p.A (GNTA) posted Share-based Compensation of $2.6 million for Q4 2025, down 11.91% sequentially from $3.0 million in Q2 2025, and up 302.76% YoY from $656638.0 in Q4 2024.
Genenta Science S.p.A (GNTA) Share-based Compensation (2020 - 2025) Analysis & Trends
Genenta Science S.p.A has reported Share-based Compensation for 5 years, with the latest figure at $2.6 million in Q4 2025.
- Quarterly Share-based Compensation rose 302.76% year-over-year to $2.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.6 million (changed N/A YoY) and the FY2025 annual result came in at $2.6 million, up 76.22% from the prior year.
- Share-based Compensation eased to $2.6 million in Q4 2025 per GNTA's latest filing, from $3.0 million in the prior quarter.
- Over five years, Share-based Compensation peaked at $3.0 million in Q2 2025 and troughed at $349089.8 in Q4 2023.
- A 4-year average of $1.5 million and a median of $1.6 million in 2023 frame the typical range for Share-based Compensation.
- The sharpest annual moves came in 2023 and 2025: Share-based Compensation sank 79.12% in 2023, then surged 302.76% in 2025.
- Over 4 years, Share-based Compensation stood at $1.7 million in 2022, then tumbled by 79.12% to $349089.8 in 2023, then jumped by 88.1% to $656638.0 in 2024, then soared by 302.76% to $2.6 million in 2025.
- According to Business Quant data, Share-based Compensation over the past three periods registered $2.6 million, $3.0 million, and $656638.0 for Q4 2025, Q2 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Genenta Science S.p.A | 25.03 Mn | -34.07 Mn | - | 2.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.64 Mn |
| Dec 31, 2025 | 2.64 Mn |
| Jun 30, 2025 | 3.00 Mn |
| Jun 30, 2025 | 3.00 Mn |
| Dec 31, 2024 | 656,637.98 |
| Dec 31, 2024 | 656,637.98 |
| Jun 30, 2024 | 804,481.33 |
| Jun 30, 2024 | 804,481.33 |
| Dec 31, 2023 | 349,089.78 |
| Dec 31, 2023 | 349,089.78 |
| Jun 30, 2023 | 1.60 Mn |
| Jun 30, 2023 | 1.60 Mn |
| Dec 31, 2022 | 1.67 Mn |
| Dec 31, 2022 | 1.67 Mn |
| Dec 31, 2020 | 373,512.22 |
| Dec 31, 2020 | 373,512.22 |